LRMR
Larimar Therapeutics, Inc.
Biotechnology · Healthcare · United States
2.47
close · 2026-10-30
value
37
cheaper than peers37
quality
31
stronger fundamentals31
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.02× | 56 |
| cash flow yield, 2 years ago | -13.1% | 54 |
| earnings yield, 2 years ago | -34.0% | 54 |
| cash flow yield, 3 years ago | -10.8% | 53 |
| earnings yield, 3 years ago | -55.5% | 52 |
| cash flow yield, 1 year ago | -27.8% | 41 |
| earnings yield, 1 year ago | -53.4% | 38 |
| cash flow yield, latest year | -44.2% | 27 |
| earnings yield, latest year | -91.9% | 22 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 3.9% | 53 |
| operating margin | 0.0% | 50 |
| return on equity | -139.6% | 20 |
3 of 4 measures available
Facts
| market cap | $257M |
| free cash flow | -$94.2M |
| employees | 71 |
| first trade | 2014-06-19 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.27 | -1.32 | -0.84 | -1.37 |
| free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M |
| net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M |
| revenue | $0 | $0 | $0 | $0 |